Ensysce Biosciences (ENSC) EBITDA (2018 - 2025)
Ensysce Biosciences (ENSC) posted quarterly EBITDA of -$3.7 million for Q3 2025, down 680.24% year-over-year from $644746.0 in Q3 2024, and down 113.71% quarter-over-quarter from -$1.8 million in Q2 2025.
Ensysce Biosciences (ENSC) EBITDA (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported EBITDA for 8 consecutive years, with -$3.7 million the latest figure, recorded in Q3 2025.
- In Q3 2025, EBITDA fell 680.24% year-over-year to -$3.7 million; the TTM figure through Sep 2025 stood at -$11.0 million (down 74.91% YoY), while the FY2024 annual figure was -$6.7 million, up 37.21% from the prior year.
- EBITDA eased to -$3.7 million in Q3 2025 per ENSC's latest filing, from -$1.8 million in the prior quarter.
- Across five years, EBITDA topped out at $644746.0 in Q3 2024 and bottomed at -$16.9 million in Q3 2021.
- Historically, EBITDA has averaged -$3.6 million across 5 years, with a median of -$2.6 million in 2023.
- Annual changes were most pronounced in 2021 — EBITDA tumbled 4071.91% — and 2024, when it jumped 123.81%.
- Ensysce Biosciences' EBITDA stood at -$2.0 million in 2021, then sank by 209.0% to -$6.2 million in 2022, then jumped by 49.11% to -$3.2 million in 2023, then retreated by 13.33% to -$3.6 million in 2024, then declined by 4.6% to -$3.7 million in 2025.
- Business Quant data shows ENSC's EBITDA at -$3.7 million in Q3 2025, -$1.8 million in Q2 2025, and -$2.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Ensysce Biosciences | 960,039.34 | -3.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -3.74 Mn |
| Jun 30, 2025 | -1.75 Mn |
| Mar 31, 2025 | -1.97 Mn |
| Dec 31, 2024 | -3.58 Mn |
| Sep 30, 2024 | 644,746.00 |
| Jun 30, 2024 | -1.96 Mn |
| Mar 31, 2024 | -1.84 Mn |
| Dec 31, 2023 | -3.16 Mn |
| Sep 30, 2023 | -2.71 Mn |
| Jun 30, 2023 | -2.29 Mn |
| Mar 31, 2023 | -2.56 Mn |
| Dec 31, 2022 | -6.20 Mn |
| Sep 30, 2022 | -6.16 Mn |
| Jun 30, 2022 | -7.06 Mn |
| Mar 31, 2022 | -4.80 Mn |
| Dec 31, 2021 | -2.01 Mn |
| Sep 30, 2021 | -16.89 Mn |
| Jun 30, 2021 | -412,617.00 |
| Mar 31, 2021 | -524,273.00 |
| Dec 31, 2020 | -1.09 Mn |